Lipids & metabolic liver disease
Noninvasive identification of probable fibrotic nonalcoholic steatohepatitis across the spectrum of glucose tolerance in the United States
Authors' conclusion
FNI is an easy and reliable test to screen for NASH and its performance is maintained in patients with diabetes, a condition that was shown to negatively influence the performance of several non-invasive scores.
Study context
- Population
- US adults in NHANES 2017–2020 with data to calculate Fibrotic NASH Index (FNI) and reliable vibration controlled transient elastography; excluded chronic viral hepatitis, significant alcohol consumption or other liver disease
- Participants
- 6,268 adults
- Outcome
- Prevalence of probable fibrotic NASH (Fibroscan-AST (FAST) score ≥ 0.35) across the spectrum of glucose tolerance, and performance of the Fibrotic NASH Index (FNI)
Methodological detailspopulation-based, NHANES 2017-2020
- Population-based
- NHANES 2017-2020
Main finding
As reported in the abstract
Probable fibrotic NASH prevalence
Overall prevalence of probable fibrotic nonalcoholic steatohepatitis (NASH)
5.9 %
95 % CI 5.2–6.7
Prevalence with normal glucose tolerance
3.7 %, 95 % CI 2-9-4.7
Prevalence with diabetes
14.7 %, 95 % CI 12.1-17.8
Observational data: associations, not effects.
Further findings
FNI performance for probable fibrotic NASH
- AUROC, overall population
- 0.93, 95 % CI 0.92-0.94
- AUROC, participants with diabetes (n = 1113)
- 0.89, 95 % CI 0.86-0.92
- FNI outperformed Fibrosis-4 in all groups
Original publication
Noninvasive identification of probable fibrotic nonalcoholic steatohepatitis across the spectrum of glucose tolerance in the United States. Diabetes Res Clin Pract. Published 23 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →